Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target ...

CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration, according to a ...

A minimally invasive procedure that targets inflamed blood vessels is giving many people with chronic knee pain lasting ...

Eylea and Eylea HD are prescription medications used to treat various eye conditions. The dosage and frequency of injections of these drugs vary based on the specific condition and the form of the ...

Bevacizumab reached 29.8% of 2025 injections, rising from 23.3% in 2024, while aflibercept 2 mg fell to 21.9% from 36.9% in 2024. Reduced Good Days copay assistance disrupted affordability for branded ...

Published online in April in JAMA Ophthalmology, the phase 3 CONDOR trial (NCT04278417) found that brolucizumab (Beovu; ...

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectiveness of ...

In what's been hailed as a "massive breakthrough," a chlamydia vaccine implant has been administered to a wild koala for the ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

Steroids, specifically corticosteroids, work by reducing inflammation that puts pressure on nerves and causes back pain. They lower levels of prostaglandins and other chemicals involved in the ...